A Phase 1 interventional study of Danuglipron in Obesity, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-20.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.
Among the 64 studies in Obesity by Pfizer, this one is the 53rd largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2024, is one of 30 in phase 1, and was the 36th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 14 · Phase 3 17
First in 2004; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 127 across the 62 interventional studies, 53,752 across the 2 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
8 of the studies in Obesity by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07725809PfizerA Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-01-13 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
Add all 8 to your calendar (.ics) → With an account.
Among the 64 studies in Obesity by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
The total number of weeks of the study is about 15 (about 4 months).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive multiple doses of danuglipron
Drug: Danuglipron
Danuglipron oral tablets
Also known as: PF-06882961
Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron
Time frame: Predose to 24 hours post danuglipron administration
Steady-state maximum observed concentration (Cmax) for danuglipron
Time frame: Predose to 24 hours post danuglipron administration
Steady-state time to reach maximum observed concentration (Tmax) for danuglipron
Time frame: Predose to 24 hours post danuglipron administration
Number of participants reporting Treatment Emergent Adverse Events (TEAEs)
Time frame: From baseline up to 28-35 days post last dose taken
Number of participants reporting clinically significant clinical laboratory abnormalities
Time frame: From baseline up to 28-35 days post last dose taken
Number of participants reporting clinically significant vital sign abnormalities
Time frame: From baseline up to 28-35 days post last dose taken
Change from baseline in body weight
Time frame: From baseline up to 28-35 days post last dose taken
Number of participants reporting clinically significant changes ECG abnormalities
Time frame: From baseline up to 28-35 days post last dose taken
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Aug 2024 to primary completion in Dec 2024, 3 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron